Get started
Author

Daniel da Silva Pereira Curado

Observed names: Curado, Daniel, Curado, Daniel da Silva Pereira, Da Silva Pereira Curado, Daniel, Daniel Curado, Daniel Da Silva Pereira Curado, Daniel da Silva Pereira
ORCID: 0000-0002-5965-4194
Observed ORCID: 0000-0002-5965-4194
OpenAlex ID: A5042656619
Clinical effectiveness of screening for age-related macular degeneration: A systematic review
2023 · Dalila Fernandes Gomes, Daniel da Silva Pereira Curado, et al. · PLoS ONE · 11
Direct cost of systemic arterial hypertension and its complications in the circulatory system from the perspective of the Brazilian public health system in 2019
2021 · Daniel da Silva Pereira Curado, Dalila Fernandes Gomes, et al. · PLoS ONE · 8
PDF
Application of natural language processing to predict final recommendation of Brazilian health technology assessment reports
2024 · Marilia Mastrocolla de Almeida Cardoso, Juliana Machado-Rugolo, et al. · International Journal of Technology Assessment in Health Care · 5
PDF
Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease
2023 · Daniela Ponce, Marilia Mastrocolla de Almeida Cardoso, et al. · Brazilian Journal of Nephrology · 3
PDF
Cost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease
2022 · Marilia Mastrocolla de Almeida Cardoso, Juliana Machado-Rugolo, et al. · Brazilian Journal of Nephrology · 2
PDF
Cost-Effectiveness Analysis and Budget Impact: Antimuscarinics and Mirabegron for the Treatment of Patients With Urge Urinary Incontinence: The Brazilian Public Health System Perspective
2020 · Fernando Zanghelini, Haliton Alves de Oliveira, et al. · Value in Health Regional Issues · 2
PDF
OD11 Application Of Natural Language Processing To Predict Final Recommendation Of Brazilian Health Technology Assessment Reports
2024 · Marilia Mastrocolla de Almeida Cardoso, Juliana Machado-Rugolo, et al. · International Journal of Technology Assessment in Health Care · 1
PDF
Exploring the COVID-19 Pandemic’s Impact on the Health Technology Assessment Process of the National Commission for the Incorporation of Technologies Into the Brazilian Health System
2023 · Marilia Mastrocolla de Almeida Cardoso, Lehana Thabane, et al. · Value in Health Regional Issues · 1
PDF
PP43 Impact Of The COVID-19 Pandemic In The Brazilian National Committee for Health Technology Incorporation (Conitec) Recommendation Process
2022 · Marilia Cardoso, Lehana Thabane, et al. · International Journal of Technology Assessment in Health Care · 1
PDF
Affordability of new drugs in the Brazilian public health system: a 13-year monitoring analysis of reimbursement decisions based on health technology assessments (2012–2024)
2026 · Daniel da Silva Pereira Curado, Marisa Santos, et al. · The Lancet Regional Health - Americas
Efficacy and safety analysis of the use of ibrutinib associated with rituximab for the first-line treatment of patients with chronic lymphocytic leukaemia
2025 · Aline do Nascimento, Daniel da Silva Pereira Curado, et al. · Hematology Transfusion and Cell Therapy
PD57 Drugs For Chronic Degenerative And Rare Diseases In The Brazilian Public Health System: Profile Of Budget Impact Analyses
2025 · Daniel Da Silva Pereira Curado, Amanda Oliveira Lyrio, et al. · International Journal of Technology Assessment in Health Care
PDF
Medicamentos incorporados no Sistema Único de Saúde: análise documental das decisões metodológicas em análises de impacto orçamentário entre 2012 e 2024
2025 · Daniel da Silva Pereira Curado, Everton Nunes da Silva · Epidemiologia e Serviços de Saúde
Drugs incorporated into the Brazilian Unified Health System: document analysis of methodological decisions in budget impact analyses between 2012 and 2024
2025 · Daniel da Silva Pereira Curado, Everton Nunes da Silva · Epidemiologia e Serviços de Saúde
Custo-Efetividade da Terapia Preemptiva versus Terapia Empírica para Manejo de Infecções Fúngicas Invasivas em Pacientes com Neutropenia Febril no Sistema Único de Saúde
2025 · Luiza Ikeda Seixas Cardoso, Daniel da Silva Pereira Curado, et al. · Epidemiologia e Serviços de Saúde
PDF
PD240 Report Of Outcomes In Health Technology Assessment For Technologies In Ultrarare Diseases In The Brazilian Public Health System
2024 · Denis Satoshi Komoda, Juliana Machado-Rugolo, et al. · International Journal of Technology Assessment in Health Care
PDF
PD185 Is The Incorporation Of Medications For Ultrarare Diseases In Brazil Predominantly Driven By Costs? A Shift In Paradigm
2024 · Daniel da Silva Pereira Curado, Juliana Machado-Rugolo, et al. · International Journal of Technology Assessment in Health Care
PDF
PP28 The Final Arguments To Incorporate Or Not Incorporate Technologies For Ultra-Rare Diseases Into The Brazilian Public Healthcare System
2024 · Monica Aparecida de Paula de Sordi, Juliana Machado-Rugolo, et al. · International Journal of Technology Assessment in Health Care
PDF
PP21 Examining Clinical Evidence: Incorporation Of Medications For Ultra-Rare Diseases – Descriptive Analysis Of Conitec Reports (2012 to 2022) – Brazil
2024 · Juliana Machado-Rugolo, Daniel da Silva Pereira Curado, et al. · International Journal of Technology Assessment in Health Care
PDF
PD02 Budget Impact Analysis: A Challenge To Incorporating Medications For Ultrarare Diseases In The Brazilian Healthcare System
2024 · Marisa Santos, Daniel da Silva Pereira Curado, et al. · International Journal of Technology Assessment in Health Care
PDF
A perspectiva individual no processo de incorporação de tecnologias para doenças ultrarraras no Brasil
2024 · Daniel Da Silva Pereira Curado, Denis Satoshi Komoda, et al. · Jornal de Assistência Farmacêutica e Farmacoeconomia
PDF
As evidências clínicas para a incorporação de medicamentos para doenças ultrarraras: uma análise descritiva dos relatórios apresentados na CONITEC de 2012 a 2022
2024 · Marilia Mastrocolla de Almeida Cardoso, Daniel Da Silva Pereira Curado, et al. · Jornal de Assistência Farmacêutica e Farmacoeconomia
PDF
Os custos são decisivos na incorporação de medicamentos para doenças ultrarraras no SUS? Uma quebra de paradigma.
2024 · Daniel Da Silva Pereira Curado, Denis Satoshi Komoda, et al. · Jornal de Assistência Farmacêutica e Farmacoeconomia
Economic Impact of Early Treatment and Tight Control in Rheumatoid Arthritis: a Cost-minimization Approach Concerning the Prescription of Biologicals Data From the Real Study
2024 · Raianni Rúbia Pacheco Silva, Paula Cristina Montina, et al. · Congresso Brasileiro de Reumatologia
PDF
Análise de custo-efetividade do cinacalcete vs. paricalcitol no tratamento do hiperparatireoidismo secundário à doença renal crônica
2023 · Daniela Ponce, Marilia Mastrocolla de Almeida Cardoso, et al. · Brazilian Journal of Nephrology
PDF
Works count: 31
Citation count: 35
H-index: 3
I10-index: 1
Year
Topic
Type